Keywords
Adverse drug reactions
Toxic epidermal necrolysis
Skin lesions
Paracetamol
Ibuprofen
Corticoids
IV immunoglobulin
How to Cite
Abstract
Background: Adverse drug reactions are harmful and unintentional events related to medication use. Stevens-Johnson Syndrome is a serious adverse drug reaction that can progress to toxic epidermal necrolysis and is related to certain medications. It can even be triggered by infections and genetic factors.
Case report: A 62-year-old female patient with high blood pressure developed severe skin lesions after self-medicating with paracetamol and ibuprofen. She recovered favorably after several treatments and admissions to the Intensive Care Unit.
Conclusions: It is important to promptly identify the triggering factors of adverse drug reactions in order to intervene appropriately. The administration of corticosteroids and IV immunoglobulin is still under discussion. Immediate attention is required to improve clinical outcomes and comprehensive treatment, thus optimizing the outcome.
Keywords: Stevens-Johnson Syndrome; Adverse drug reactions; Toxic epidermal necrolysis; Skin lesions; Paracetamol; Ibuprofen; Corticoids; IV immunoglobulin.
References
1. Bergmann KC, Ring J. History of Allergy. primera ed. KARGER; 2014.
2. Orellana-Cobos DF, Delgado-Andrade PG, Orellana-Cobos AB, Quituisaca-Vishñay BF. Síndrome de Stevens-Johnson por consumo de fármacos: reporte de caso. Rev Fac Ciencias Méd 2022; 09: 40 (3).
3. Gibson A, Deshpande P, Campbell C, Krantz M, et al. Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions. J Allergy Clin Inmunol 2023; 151 (2): 289-300.
4. Frantz R, Huang S, Are A, Motoparthi K. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management. Medicina (Kaunas) 2021; 57 (9): 895.
5. Duong T, Valeyrie-Allanore L, Wolkenstein P, Chosidow O. Severe cutaneous adverse reactions to drugs. Lancet 2017. https://pubmed.ncbi.nlm.nih.gov/28476287/
6. Hsu D, Brieva J, Silverberg N, Silverberg J. Morbidity and mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults. J Invest Dermatol 2016; 136 (7): 1387-97.
7. Marti-Marti D, Morgado-Carrasco C, Carrera F, Alamon-Reig L, et al. Stevens-Johnson syndrome/toxic epidermal necrolysis-like cutaneous lupus erythematosus. A case series with long-term follow-up. J Eur Acad Dermatol Venerol 2021; 36 (2): 135-9.
8. Falconí Chávez DS, Jami Carrera JE. Síndrome de Steven-Johnson y necrolisis epidérmica toxica: revisión bibliográfica actualizada. Ciencia Latina Rev Cient Multidisc 2022; 6 (5): 643-61.
9. Chen CB, Kuo KL, Wang CW, Lu CW, et al. Detecting Lesional Granulysin Levels for Rapid Diagnosis of Cytotoxic T lymphocyte-Mediated Bullous Skin Disorders. J Allergy Clin Inmunol Pract 2021; 9 (3): 1327-1337.
10. Copaescu A, Mouthouris E, Vogrin S, James F, et al. The Role of In Vivo and Ex Vivo Diagnostic Tools in Severe Delayed Immune-Mediated Adverse Antibiotic Drug Reactions. J Allergy Clin Immunol 2021; 9 (5): 2010-2025.
11. Brüggen M, Le S, Walsh S, Toussi A, et al. Supportive care in the acute phase of Stevens-Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary Delphi-based consensus. Br J Dermatol 2021; 185 (3): 616-26.
12. Krajewski A, Maciejewska-Markiewicz D, Jakubczyk K, Markowska M, et al. Impact of multiple medical interventions on mortality, length of hospital stay and reepithelialization time in Toxic Epidermal Necrolysis, Steven-Johnsons Syndrome, and TEN/SJS Overlap - Metanalysis and metaregression of observational studies. Burns 2022; 48 (2): 163-80.
13. Haur Yueh L. Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis. UpToDate 2025. https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis?search=stevens%20johnson%20syndrome&source=search_result&selectedTitle=1%7E150&usage_type=default&display_rank=1#H.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2025 Revista Alergia México